Uterine Artery Embolization(UAE) Versus High-Intensity-Focused-Ultrasound(HIFU) for Treatment of Uterine Fibroids

NCT01834703 | Terminated DMC

• 1 other identifier: VIR-13-02
• Study Type: interventional
• Target: 85
• Locations: 1 country
• Sites: 2

Brief Summary

This study aimed to evaluate the clinical effectiveness and adverse effects of Uterine Artery Embolization (UAE), High-Intensity-Focused-Ultrasound (HIFU) in treating patients with uterine fibroid.

Conditions

Uterine Fibroids

Outcome Measures

Primary Outcomes (1)

• Treatment success rate

  Technical success of treatment procedure and absence of symptoms of fibroid

  6 months

Secondary Outcomes (4)

• Incidence of procedure related complication

  1, 3, 6, 12 months after treatment

• volume change of the fibroids

  6, 12 months after treatment

• Degree of infarction of the fibroids

  3, 15 months after treatment

• Vascularity of the fibroids

  6, 12 months after treatment

Study Arms (2)

UAE treatment

ACTIVE COMPARATOR

After randomization, patient recruited will be arranged to receive UAE treatment. 100 patients will be recruited for UAE treatment

Procedure: UAE

HIFU

ACTIVE COMPARATOR

After randomization, patient recruited will be arranged to receive HIFU treatment. 100 patients will be recruited for HIFU treatment

Procedure: HIFU

Interventions

UAE PROCEDURE

The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.

UAE treatment

HIFU PROCEDURE

Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.

HIFU

Eligibility Criteria

• Age: 30 Years - 47 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Female gender
• Age between 30 and 47
• Pre or peri menopausal with Follicle-stimulating hormone (FSH) less than 40 mIU/ml
• Weight less than 140kg (or 310lbs) and Body Mass Index (BMI) less than 33
• Cervical cytology no more severe than low grade SIL
• Negative urine pregnancy test
• Uterine size less than 24 weeks based on physical exam assessment
• History of uterine leiomyoma causing symptoms of bleeding, pressure, or pain. Excessive uterine bleeding will be evidenced by either one of the following-profuse bleeding with flooding or clots or repetitive periods lasting for more than 8 days; or anemia due to acute or chronic blood loss OR pelvic discomfort caused by leiomyomata, either acute and severe or chronic lower abdominal or low back pressure or bladder pressure with urinary frequency not due to urinary tract infection
• Dominant intramural fibroid greater than or equal to 3 cm and less than or equal to 12 cm on imaging.
• Good health other than history of leiomyomas. Chronic medications may be acceptable at the discretion of the research team.
• No future fertility wish.
• Are using abstinence, mechanical (condoms, diaphragms) or sterilization methods of contraception and are willing to continue using them throughout the study.
• Willing and able to give informed consent.
• Willing and able to comply with study requirements.
• Normal menstrual cycle with endometrial pathology excluded

You may not qualify if:

• Significant abnormalities in the history, physical or laboratory examination
• History of or current thromboembolic event (deep vein thrombosis, pulmonary embolus, stroke)
• Other pelvic mass indicated by history or MR imaging such as endometriosis, ovarian tumor, acute or chronic pelvic inflammatory disease
• Desire for future pregnancy
• Pregnant or Positive pregnancy test
• Lactation
• Unexplained vaginal bleeding
• Untreated severe cervical dysplasia
• Intrauterine device
• Need for interval use of narcotics
• Extensive scarring along anterior lower abdominal wall (greater than 50% of area) or scar tissue or surgical clips in the direct path of the HIFU
• Pedunculated submucosal or subserosal fibroid of size ≧5cm and with a stalk less than 25% of the maximal fibroid diameter.
• Genetic causes of leiomyomata
• Known recent rapid growth of fibroids, defined as a doubling in size in 6 months
• Patient unwilling to receive non-surgical treatment

Sponsors & Collaborators

• Chinese University of Hong Kong: lead
• Prince of Wales Hospital, Shatin, Hong Kong: collaborator

Study Sites (2)

Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong

Hong Kong, Hong Kong

Location

Department of Obstectrics and Gynaecology, Prince of Wales Hospital

Hong Kong, Hong Kong

Location

MeSH Terms

Conditions

Leiomyoma

Condition Hierarchy (Ancestors)

Neoplasms, Muscle Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Study Officials

• Simon CH Yu, MD, FRCR

  Chinese University of Hong Kong

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 4, 2013
• First Posted: April 18, 2013
• Study Start: May 1, 2009
• Primary Completion: December 1, 2015
• Study Completion: December 1, 2015
• Last Updated: August 30, 2019

Record last verified: 2016-02

Data Sharing

• IPD Sharing: Will not share

Locations

HK (2)